NeuroKaire Announces BrightKaire Blood Test To Reduce ‘Trial & Error’ Antidepressant Prescribing

NeuroKaire announced the U.S. launch of a clinical blood test called BriteKaire to reduce the 'trial and error' approach to finding the right antidepressant for people with major depressive disorder (MDD). Using its proprietary AI platform to analyze personalized patient data—including genetic background, and microscopic features of patient-derived neurons—BrightKaire provides a detailed report demonstrating how well the individual will respond to different antidepressants. The results also include an individual's likelihood for adverse events. That information is shared with the patient's clinical team, resulting in more accurate, faster, and effective medication, reduced side effects, and . . .